Special clinical interests in theranostics, molecular imaging and translational research.
Nat graduated in medicine from the University of Western Australia and then completed a fellowship in nuclear medicine at the University of Michigan. Apart from undergraduate science, research and medical degrees, he also holds masters degrees in medicine, oncology, health service management and business administration, and is currently completing an online masters in molecular oncology with the European School of Medical Oncology.
From 2001 – 2006, Nat was the inaugural head of the Western Australian PET/cyclotron service based at Sir Charles Gairdner Hospital. He has also held head of department positions in Nuclear Medicine and Internal Medicine at Royal Perth Hospital and Fremantle Hospital.
Currently, Nat is an an adjunct clinical professor in Medicine at Curtin University and Notre Dame University Australia. He also works consultant nuclear physician and acute medicine physician at Fiona Stanley Hospital, and general physician at St John of God Hospital Murdoch.
With a strong track record in developing clinical and research services in the public and private sectors, Nat’s research interests are in new molecular imaging and targeted therapeutic agents in neurosciences and oncology. He is the co-investigator on a number of grants, a principal investigator in several multicentre clinical trials, and a co-author on over 50 peer reviewed publications, predominantly in the areas of molecular imaging and therapy in neuroscience and oncology.
In 2015, Nat founded Theranostics Australia, now fully owned by GenesisCare, where he remains in the position of group clinical director. He is committed to expanding the field of theranostics with GenesisCare in Australia and overseas.
- Hollywood Private Hospital (Theranostics)
- Hurstville (Oncology)
- Global Telehealth Consultation Service
- Theranostics – Lutetium and Actinium
- Prostate Cancer
- Neuroendocrine tumours
- Thyroid cancer including anaplastic
To read more, follow A/Prof Lenzo via his LinkedIn account here.